Profil
Cecilia Ann-Christin Malmborg Hager is currently Chief Executive Officer at Lead Biologics International AB. She is Director at PainDrainer AB, Diaprost AB, Hager Consulting AB, and Colzyx AB. She serves as Independent Director at SenzaGen AB since 2019 and at NanoEcho AB since 2022.
Former roles include Chief Executive Officer at WC Likvid AB, Sista versen 26366 AB, Executive Foundation Lund, and Xlmmune AB. She was Chief Executive Officer & Director at Cantargia AB from 2013 to 2014.
She worked as Investment Director at Lund University Bioscience AB from 2009 to 2011.
Other former positions include Independent Director at Immunovia AB, Director & Business Manager at ProNoxis AB, Director at Bulb Intelligence AB and Avena Partners AB, and Vice President-Business Development at Alligator Bioscience AB. Education includes graduate and doctorate degrees from the University of Lund.
Postes actifs de Anki Malmborg Hager
| Sociétés | Poste | Début |
|---|---|---|
| SENZAGEN AB | Directeur/Membre du Conseil | 17/06/2019 |
| NANOECHO AB | Directeur/Membre du Conseil | 01/01/2022 |
Hager Consulting AB | Directeur/Membre du Conseil | - |
PainDrainer AB
PainDrainer AB Packaged SoftwareTechnology Services Develops digital pain management tools | Directeur/Membre du Conseil | 01/09/2019 |
Diaprost AB
Diaprost AB Miscellaneous Commercial ServicesCommercial Services Provides research services | Directeur/Membre du Conseil | - |
Colzyx AB
Colzyx AB Medical SpecialtiesHealth Technology Develops wound dressing care products | Directeur/Membre du Conseil | - |
Anciens postes connus de Anki Malmborg Hager
| Sociétés | Poste | Fin |
|---|---|---|
Avena Partners AB | Directeur/Membre du Conseil | 26/09/2024 |
Lund University Bioscience AB
Lund University Bioscience AB Investment ManagersFinance LU Bio's investment objective is to create value growth in their innovations for all stakeholders such as the inventors, Lund University, investors and society. Their investment strategy seeks to invest in start-up, early-stage or early-expansion phase projects in the life science field which require capital. They invest across the Nordic region of Sweden, Denmark, Finland and Norway, with a particular focus on Sweden. LU Bio is an active investment partner. They provide both capital and industrial development know-how with the goal of accelerating efficient development of life science innovations. They look to develop high-growth, high-technology and focused portfolio firms. The firm aims to grow defensible and dominant market positions. | Directeur en chef des Investissements | - |
ProNoxis AB
ProNoxis AB Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs to treat chronic inflammation | Directeur/Membre du Conseil | - |
| ░░ ░░░░░░ ░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░ ░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░ | - |
Formation de Anki Malmborg Hager
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 18 |
|---|---|
Alligator Bioscience AB
Alligator Bioscience AB BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops antibodies for the treatment of cancers | Health Technology |
University of Lund
University of Lund Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lund University Bioscience AB
Lund University Bioscience AB Investment ManagersFinance LU Bio's investment objective is to create value growth in their innovations for all stakeholders such as the inventors, Lund University, investors and society. Their investment strategy seeks to invest in start-up, early-stage or early-expansion phase projects in the life science field which require capital. They invest across the Nordic region of Sweden, Denmark, Finland and Norway, with a particular focus on Sweden. LU Bio is an active investment partner. They provide both capital and industrial development know-how with the goal of accelerating efficient development of life science innovations. They look to develop high-growth, high-technology and focused portfolio firms. The firm aims to grow defensible and dominant market positions. | Finance |
Immunovia AB
Immunovia AB Pharmaceuticals: MajorHealth Technology Provides blood-based test for diagnosis of pancreatic cancer | Health Technology |
ProNoxis AB
ProNoxis AB Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs to treat chronic inflammation | Health Technology |
WC Likvid AB
WC Likvid AB Real Estate DevelopmentFinance Owns and manages movable and immovable property | Finance |
Cantargia AB
Cantargia AB Pharmaceuticals: MajorHealth Technology Creates and develops antibody therapeutics for the treatment of leukemia | Health Technology |
Sista versen 26366 AB
Sista versen 26366 AB Pharmaceuticals: MajorHealth Technology Discovers treatments for inflammatory disorders | Health Technology |
SenzaGen AB
SenzaGen AB BiotechnologyHealth Technology Develops in vitro test methods for prediction of chemical and protein sensitizers | Health Technology |
Diaprost AB
Diaprost AB Miscellaneous Commercial ServicesCommercial Services Provides research services | Commercial Services |
Hager Consulting AB | |
Avena Partners AB | |
Bulb Intelligence AB | |
Executive Foundation Lund
Executive Foundation Lund Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xlmmune AB
Xlmmune AB Pharmaceuticals: MajorHealth Technology Engages in pharmaceutical preparation | Health Technology |
Nanoecho AB
Nanoecho AB Medical SpecialtiesHealth Technology Develops medical ultrasound imaging equipment to treat rectal cancer | Health Technology |
Colzyx AB
Colzyx AB Medical SpecialtiesHealth Technology Develops wound dressing care products | Health Technology |
PainDrainer AB
PainDrainer AB Packaged SoftwareTechnology Services Develops digital pain management tools | Technology Services |
















